600422 KPC Pharmaceuticals, Inc.
- 16.63
- -0.16-0.95%
About KPC Pharmaceuticals, Inc. Company
The company was founded in March 1951 and listed on the Shanghai Stock Exchange in December 2000. The company has deep professional pharmaceutical experience, and is a national key high-tech enterprise and one of the top 100 enterprises in China's pharmaceutical industry. Relying on Yunnan's rich plant resources, Kunyao Group has successively developed more than 40 new natural medicine products with advanced levels at home and abroad, including the three major series of green artemisia, and specialty traditional Chinese medicine, and traditional Chinese medicine. At the same time, it has inherited the essence of Chinese medicine and has created a number of fine Chinese medicines represented by Shenlingjian spleen and stomach granules, liver relief granules, etc., gradually forming the four core business patterns of chronic disease management, healthy consumption, overseas international, and beautiful health. The company's industry is pharmaceutical manufacturing. Its business area covers the entire pharmaceutical industry chain, and its core business covers fields such as drug research and development, production and sales, pharmaceutical distribution, and the health industry. The company's core products include Kunyao Hemocalcitone series, artemisinyl ether series, Kunming Traditional Chinese Medicine Shenling Spleen and Stomach Granules, Hepatic Soothing Granules, Incense Stomach Calciferol softgels, sodium hyaluronate injections, etc. The company was selected as the “National Technological Innovation Demonstration Enterprise” assessed by the Ministry of Industry and Information Technology, the “2019 China Pharmaceutical Innovation Enterprise Top 100”, “Top 500 Chinese Enterprise Patents”, and “2022 Chinese Pharmacy Staff Recommendation Rate Brand”, ranked 13th in the “2022 Top 100 Proprietary Chinese Medicine Companies List” and ranked 12th in the “2022 Top 30 Chinese Medicine Listed Companies”. It won the “2023 Best Practice Case for Listed Company Directors” by the China Association of Listed Companies, Securities Daily Honors include the “ESG Pioneer Practitioner” honor, the “Social Responsibility (S) Pioneer Enterprise Award” issued by the Financial Federation and the China Environmental Protection Federation, and the top 100 enterprises in the national pharmaceutical manufacturing industry.
Company Profile
Company Executives
- Name
- Position
- Salary
- huawei qiu
- Chairman, Directors, Nomination Committee Members, Chairman of the Strategy Committee
- --
- hongshen li
- Vice Chairman, Directors, Strategy Committee Member
- --
- wei yan
- Vice Chairman, Directors, President, Strategy Committee Member
- 678.30K
- hui zhou
- Directors, Strategy Committee Member
- --
- zheng liang
- Directors, Member of the Audit and Risk Control Committee
- --
- ting guo
- Directors, Member of the Remuneration and Assessment Committee
- --
- ke liu
- Independent Directors, Chairman of the Nomination Committee, Member of the Audit and Risk Control Committee
- 100.00K
- zhi yang
- Independent Directors, Strategy Committee Member, Chairman of the Remuneration and Assessment Committee
- 100.00K
- jinguo xin
- Independent Directors, Chairman of the Audit and Risk Control Committee, Nomination Committee Members, Member of the Remuneration and Assessment Committee
- 100.00K
- mengxun zhang
- Board Secretary, VP
- 458.30K
- yu dong
- Securities Affairs Representative
- --
- jiang zhong
- Chairman of the Supervisory Board, Auditors
- --
- kang deng
- Auditors
- --
- jinfeng shao
- Auditors
- --
- junfeng liu
- VP
- 779.20K
- cheng sun
- VP
- --
- li meng
- VP
- 608.30K
- kai xi
- VP
- 396.70K
- tong gao
- VP
- --
- zhiqiang sun
- Chief Financial Officer
- 421.70K
- wensen zhang
- Employee Supervisors
- 300.00K
- linxi li
- Employee Supervisors
- 450.00K
No Data
